These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6304300)

  • 21. Strategies in neuropeptide receptor binding research.
    Quirion R; Gaudreau P
    Neurosci Biobehav Rev; 1985; 9(3):413-20. PubMed ID: 2999656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterisation and visualisation of [3H]dermorphin binding to mu opioid receptors in the rat brain. Combined high selectivity and affinity in a natural peptide agonist for the morphine (mu) receptor.
    Amiche M; Sagan S; Mor A; Pelaprat D; Rostene W; Delfour A; Nicolas P
    Eur J Biochem; 1990 May; 189(3):625-35. PubMed ID: 2161761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical characterization of cellular hormone receptors.
    Jüppner H; Hesch RD
    Curr Top Pathol; 1991; 83():53-69. PubMed ID: 1672514
    [No Abstract]   [Full Text] [Related]  

  • 24. Parathyroid hormone receptors of renal cortex: specific binding of biologically active, 125I-labeled hormone and relationship to adenylate cyclase activation.
    Di Bella FP; Dousa TP; Miller SS; Arnaud CD
    Proc Natl Acad Sci U S A; 1974 Mar; 71(3):723-6. PubMed ID: 4362630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of the "tethered-ligand" receptor in thrombin inhibition of platelet adenylate cyclase.
    Seiler SM; Michel IM; Fenton JW
    Biochem Biophys Res Commun; 1992 Feb; 182(3):1296-302. PubMed ID: 1371679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods.
    Ehlert FJ
    Mol Pharmacol; 1988 Feb; 33(2):187-94. PubMed ID: 2828914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of forskolin binding sites in rat brain membranes using [14,15-3H]14,15-dihydroforskolin as a ligand.
    Schmidt K; Munshi R; Baer HP
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Feb; 325(2):153-8. PubMed ID: 6538936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of dopamine-activated adenylate cyclase and dopamine binding by opiate receptors in rat striatum.
    Gentleman S; Parenti M; Neff NH; Pert CB
    Cell Mol Neurobiol; 1983 Mar; 3(1):17-26. PubMed ID: 6309392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a general anesthesia receptor.
    LaBella FS
    Can J Physiol Pharmacol; 1981 May; 59(5):432-42. PubMed ID: 6263435
    [No Abstract]   [Full Text] [Related]  

  • 30. Co-operative regulation of ligand binding to melanocortin receptor subtypes: evidence for interacting binding sites.
    Kopanchuk S; Veiksina S; Petrovska R; Mutule I; Szardenings M; Rinken A; Wikberg JE
    Eur J Pharmacol; 2005 Apr; 512(2-3):85-95. PubMed ID: 15840392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activities of deglycosylated thyrotropin at the thyroid membrane receptor-adenylate cyclase system.
    Amr S; Menezez-Ferreira M; Shimohigashi Y; Chen HC; Nisula B; Weintraub BD
    J Endocrinol Invest; 1985 Dec; 8(6):537-41. PubMed ID: 3009595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rat skeletal muscle cell line (L6) expresses specific adrenomedullin binding sites but activates adenylate cyclase via calcitonin gene-related peptide receptors.
    Coppock HA; Owji AA; Bloom SR; Smith DM
    Biochem J; 1996 Aug; 318 ( Pt 1)(Pt 1):241-5. PubMed ID: 8761478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
    Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
    Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay.
    Barta P; Volkova M; Dascalu A; Spiegelberg D; Trejtnar F; Andersson K
    J Pharmacol Toxicol Methods; 2014; 70(2):145-51. PubMed ID: 25084055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morphiceptin: biphasic inhibition of mu-opiate receptor ligands.
    Villiger JW
    Pharmacol Biochem Behav; 1984 Nov; 21(5):705-6. PubMed ID: 6096895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand.
    Costa T; Ogino Y; Munson PJ; Onaran HO; Rodbard D
    Mol Pharmacol; 1992 Mar; 41(3):549-60. PubMed ID: 1312216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower efficacy: interaction with an inhibitory receptor or partial agonism?
    Rovati GE; Nicosia S
    Trends Pharmacol Sci; 1994 May; 15(5):140-4. PubMed ID: 7754531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of Gila monster venom with secretin receptors in rat pancreatic membranes.
    Gillet L; Robberecht P; Waelbroeck M; Camus JC; De Neef P; König W; Christophe J
    Peptides; 1984; 5(2):407-9. PubMed ID: 6089139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
    Gordon JC; Edwards P; Elmore CS; Lazor LA; Paschetto K; Bostwick R; Sylvester M; Mauger R; Scott C; Aharony D
    Eur J Pharmacol; 2010 Dec; 649(1-3):59-63. PubMed ID: 20854803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin.
    Laburthe M; Amiranoff B; Boige N; Rouyer-Fessard C; Tatemoto K; Moroder L
    FEBS Lett; 1983 Aug; 159(1-2):89-92. PubMed ID: 6307754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.